Kathryn Romano sold $201k of KRYS
Chief Accounting Officer at Krystal Biotech, Inc.. 750 shares at an average of $267.60, traded Mar 2, 2026, filed Mar 3, 2026.
Score components
- +15RoleOfficer
- +12Trade size$201k at market
- 0Share of holdings soldSold 3.2% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.1%, 3m +11.1%, 6m +37.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001801385-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | MOption exercise Common Stock10b5-1 | +7,500 | $0.00 | $0 | 26,068 | Mar 3, 2026 |
| Feb 27, 2026 | FTax withholding Common Stock10b5-1 | -3,262 | $275.64 | $899k | 22,806 | Mar 3, 2026 |
| Feb 27, 2026 | MOption exercise Common Stock10b5-1 | +550 | $0.00 | $0 | 23,356 | Mar 3, 2026 |
| Feb 27, 2026 | FTax withholding Common Stock10b5-1 | -240 | $275.64 | $66k | 23,116 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -750 | $267.60 | $201k | 22,366 | Mar 3, 2026 |
| Feb 27, 2026 | MOption exercise Performance Stock Unitsderivative10b5-1 | -7,500 | $0.00 | $0 | 0 | Mar 3, 2026 |
| Feb 27, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -550 | $0.00 | $0 | 1,650 | Mar 3, 2026 |
| Feb 27, 2026 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +13,575 | $0.00 | $0 | 13,575 | Mar 3, 2026 |
| Feb 27, 2026 | AGrant or award Restricted Stock Unitsderivative10b5-1 | +5,442 | $0.00 | $0 | 5,442 | Mar 3, 2026 |
Related signals
Other insiders at Krystal Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $9.0M 25,000 shares | -2% | |
| 33Weak | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $9.0M 25,000 shares | -2% | |
| 50Moderate | KRYSsell Krystal Biotech, Inc. | Dino A Rossi director | $8.2M 25,000 shares | -33% | |
| 15Weak | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $347k 1,000 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $7.7M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $7.7M 25,000 shares | -2% | |
| 42Moderate | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $194k 642 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $6.6M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $6.6M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Daniel Janney director | $3.3M 11,803 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.